http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101887432-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-912 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 2016-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101887432-B1 |
| titleOfInvention | Medicine for disease related with human cornea endothelial cell with Transcription factor 4 |
| abstract | The present invention relates to a therapeutic agent for a human corneal endothelial cell disease comprising TCF4 gene or protein, and TCF4 of the present invention is found to regulate functions of mitochondrial function, energy production, autophagy, and cell proliferation in human corneal endothelial cells . The introduction of TCF4 into human corneal endothelial cells means that the regenerating ability of the corneal endothelial cells can be restored and the human corneal endothelial cell disease such as corneal scarring or corneal opacity can be healed. |
| priorityDate | 2016-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.